Fox Run Management’s Bicycle Therapeutics BCYC Stock Holding History

Fox Run Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,771	Closed	-$140K	–	914
2025 Q4	$140K	Buy	+19,771	New	+$146K	0.02%	842

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's BCYC Position: Q1 2026 in Review

Fox Run Management sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 19,771 shares — an estimated $140K sold.

Fox Run Management first reported a position in BCYC in Q4 2025 and held it in 1 quarter. The position peaked at $140K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Fox Run Management reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 19,771 Bicycle Therapeutics shares in Q1 2026, an estimated $140K.
Fox Run Management first reported a position in Bicycle Therapeutics in Q4 2025 and held it in 1 quarter.
Fox Run Management's Bicycle Therapeutics position peaked at $140K in Q4 2025.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.